Literature DB >> 21750178

Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.

David B Lovejoy1, Patric J Jansson, Ulf T Brunk, Jacky Wong, Prem Ponka, Des R Richardson.   

Abstract

The metal-chelating compound Dp44mT is a di-2-pyridylketone thiosemicarbazone (DpT) which displays potent and selective antitumor activity. This compound is receiving translational attention, but its mechanism is poorly understood. Here, we report that Dp44mT targets lysosome integrity through copper binding. Studies using the lysosomotropic fluorochrome acridine orange established that the copper-Dp44mT complex (Cu[Dp44mT]) disrupted lysosomes. This targeting was confirmed with pepstatin A-BODIPY FL, which showed redistribution of cathepsin D to the cytosol with ensuing cleavage of the proapoptotic BH3 protein Bid. Redox activity of Cu[Dp44mT] caused cellular depletion of glutathione, and lysosomal damage was prevented by cotreatment with the glutathione precursor N-acetylcysteine. Copper binding was essential for the potent antitumor activity of Dp44mT, as coincubation with nontoxic copper chelators markedly attenuated its cytotoxicity. Taken together, our studies show how the lysosomal apoptotic pathway can be selectively activated in cancer cells by sequestration of redox-active copper. Our findings define a novel generalized strategy to selectively target lysosome function for chemotherapeutic intervention against cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750178     DOI: 10.1158/0008-5472.CAN-11-1218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

1.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).

Authors:  Patric J Jansson; Tetsuo Yamagishi; Akanksha Arvind; Nicole Seebacher; Elaine Gutierrez; Alexandra Stacy; Sanaz Maleki; Danae Sharp; Sumit Sahni; Des R Richardson
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

Review 2.  Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.

Authors:  Sharleen V Menezes; Sumit Sahni; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2017-06-14       Impact factor: 5.157

3.  Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.

Authors:  Lina Al-Akra; Dong-Hun Bae; Sumit Sahni; Michael L H Huang; Kyung Chan Park; Darius J R Lane; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2018-01-05       Impact factor: 5.157

4.  Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.

Authors:  Paul T Bremer; Sabine Pellett; James P Carolan; William H Tepp; Lisa M Eubanks; Karen N Allen; Eric A Johnson; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-05-19       Impact factor: 15.419

5.  The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.

Authors:  Danuta S Kalinowski; Patric J Jansson; Zaklina Kovacevic; Des R Richardson
Journal:  Redox Rep       Date:  2013-02-19       Impact factor: 4.412

6.  The iron chelator Dp44mT suppresses osteosarcoma's proliferation, invasion and migration: in vitro and in vivo.

Authors:  Pengcheng Li; Xun Zheng; Kangquan Shou; Yahui Niu; Chao Jian; Yong Zhao; Wanrong Yi; Xiang Hu; Aixi Yu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

7.  Metal-binding effects of sirtuin inhibitor sirtinol.

Authors:  Eman A Akam; Ritika Gautam; Elisa Tomat
Journal:  Supramol Chem       Date:  2015-10-15       Impact factor: 1.688

8.  Increased generation of intracellular reactive oxygen species initiates selective cytotoxicity against the MCF-7 cell line resultant from redox active combination therapy using copper-thiosemicarbazone complexes.

Authors:  Fady N Akladios; Scott D Andrew; Christopher J Parkinson
Journal:  J Biol Inorg Chem       Date:  2016-03-07       Impact factor: 3.358

Review 9.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

Review 10.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.